-
171.发明申请公开(公告)号：US20200157176A1
公开(公告)日：2020-05-21
申请号：US16778915
申请日：2020-01-31
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , A61K39/00 , C07K14/47 , C07K14/635 , C07K14/725 , C07K16/28 , C12N5/0783 , C12Q1/6886 , G01N33/574
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
172.发明申请公开(公告)号：US20200155602A1
公开(公告)日：2020-05-21
申请号：US16750908
申请日：2020-01-23
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20200031870A1
公开(公告)日：2020-01-30
申请号：US16599258
申请日：2019-10-11
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Steffen WALTER , Jens FRITSCHE , Colette SONG , Harpreet SINGH
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
174.发明申请公开(公告)号：US20200010531A1
公开(公告)日：2020-01-09
申请号：US16582046
申请日：2019-09-25
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , C12N5/0783 , C07K16/28 , C07K14/635 , A61K39/00 , G01N33/574 , C07K14/725 , C12Q1/6886 , C07K14/47
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
175.发明申请公开(公告)号：US20200000897A1
公开(公告)日：2020-01-02
申请号：US16446384
申请日：2019-06-19
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Linus BACKERT , Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
176.发明申请公开(公告)号：US20200000895A1
公开(公告)日：2020-01-02
申请号：US16030725
申请日：2018-07-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Linus BACKERT , Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
177.发明申请公开(公告)号：US20200000848A1
公开(公告)日：2020-01-02
申请号：US16422335
申请日：2019-05-24
Applicant: Immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
178.发明申请公开(公告)号：US20190270784A1
公开(公告)日：2019-09-05
申请号：US16305686
申请日：2016-04-22
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Claudia WAGNER , Julia LEIBOLD , Colette SONG
IPC: C07K14/47 , A61K39/00 , C07K14/74 , C12N5/0783 , A61K35/17 , C07K16/30 , C07K16/28 , A61P35/00 , G16B20/20 , G01N33/574 , C12Q1/6886 , C07K14/725
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
179.发明申请公开(公告)号：US20190092823A1
公开(公告)日：2019-03-28
申请号：US16211892
申请日：2018-12-06
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC: C07K14/47 , A61K39/00 , C12N15/115 , C12N15/10 , C07K14/74 , C07K14/725 , C07K16/30 , G01N33/574 , C12N5/0783
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
180.发明申请公开(公告)号：US20190091313A1
公开(公告)日：2019-03-28
申请号：US16212783
申请日：2018-12-07
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Colette SONG
IPC: A61K39/00 , C07K16/18 , G06F19/20 , C07K16/28 , C12N15/115 , C07K14/47 , C07K16/30 , C07K14/74 , C12N5/0783 , A61K35/17 , C07K14/705 , A61K35/12
CPC classification number: A61K39/0011 , A61K35/17 , A61K39/001102 , A61K2035/124 , A61K2039/505 , A61K2039/5158 , A61K2039/572 , A61P35/00 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/18 , C07K16/2833 , C07K16/3038 , C07K2317/73 , C07K2317/76 , C07K2319/33 , C07K2319/55 , C12N5/0636 , C12N15/115 , C12N2310/16 , G16B25/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
238
records
(took 0.056 seconds)
